Separation of fast from slow anabolism by site-specific PEGylation of insulin-like growth factor I (IGF-I).
about
Optimizing IGF-I for skeletal muscle therapeuticsInsulinotropic treatments exacerbate metabolic syndrome in mice lacking MeCP2 function.The complexity of the IGF1 gene splicing, posttranslational modification and bioactivityPEGylated insulin-like growth factor-I affords protection and facilitates recovery of lost functions post-focal ischemia.Validation of serum IGF-I as a biomarker to monitor the bioactivity of exogenous growth hormone agonists and antagonists in rabbits.Molecular, physiological, and motor performance defects in DMSXL mice carrying >1,000 CTG repeats from the human DM1 locus.Peripheral nerve and neuromuscular junction pathology in Pompe diseaseCorrecting Neuromuscular Deficits With Gene Therapy in Pompe DiseaseThe pro-forms of insulin-like growth factor I (IGF-I) are predominant in skeletal muscle and alter IGF-I receptor activation.Control of IGFBP-2 Expression by Steroids and Peptide Hormones in VertebratesNew Modulators for IGF-I Activity within IGF-I Processing Products.Polyethylene glycol-coupled IGF1 delays motor function defects in a mouse model of spinal muscular atrophy with respiratory distress type 1.Differentiation defects in primary motoneurons from a SMARD1 mouse model that are insensitive to treatment with low dose PEGylated IGF1Functional improvement in mouse models of familial amyotrophic lateral sclerosis by PEGylated insulin-like growth factor I treatment depends on disease severity.
P2860
Q26825444-F2A00986-20E5-4ACB-9FE0-D44C6164602BQ30435678-220C94D9-3EED-4341-AFFB-8837EE8E70B9Q33619027-8331407E-361E-4D45-90D5-84EFABBA88C9Q33670730-29D4FC29-A7E1-407B-8952-E0D25399E25AQ34424169-54FBE747-07A6-4E9F-9E21-61E43CB1AE29Q34499428-1C65C4B7-7CCF-4DA0-9200-CD66CC2EE531Q34920690-61C24C4F-0CC2-417F-9C8D-044C700A808AQ35903220-CF327535-20AF-4816-975B-514133E9F278Q36628478-3776C4D9-C786-4D32-92E3-9FCD6EA444D6Q37700246-D0AB5CE6-A333-455D-82AA-458B1A24BDBCQ38094701-4406A7B1-B988-40A0-9AA5-E98B5A2F6162Q39219980-B5C8ED0D-7624-4E01-9372-4751FA84F7D8Q42013925-B88EFF0B-42EB-4911-A31B-5E3BF2F3B60DQ45881053-3DA68B78-E1E0-4488-A5AC-580D1C296573
P2860
Separation of fast from slow anabolism by site-specific PEGylation of insulin-like growth factor I (IGF-I).
description
2011 nî lūn-bûn
@nan
2011 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Separation of fast from slow a ...... -like growth factor I (IGF-I).
@ast
Separation of fast from slow a ...... -like growth factor I (IGF-I).
@en
type
label
Separation of fast from slow a ...... -like growth factor I (IGF-I).
@ast
Separation of fast from slow a ...... -like growth factor I (IGF-I).
@en
prefLabel
Separation of fast from slow a ...... -like growth factor I (IGF-I).
@ast
Separation of fast from slow a ...... -like growth factor I (IGF-I).
@en
P2093
P2860
P50
P356
P1476
Separation of fast from slow a ...... -like growth factor I (IGF-I).
@en
P2093
Andreas Schaubmar
Angelika Schuler
Bettina Sobottka
Chris van der Poel
Christian Staudenmaier
Dietrich Tuerck
Eginhard Schick
Friederike Hesse
Friedrich Metzger
Hans-Joachim Schoenfeld
P2860
P304
19501-19510
P356
10.1074/JBC.M110.172189
P407
P577
2011-04-01T00:00:00Z